Histological improvement of non-alcoholic steatohepatitis with a prebiotic: a pilot clinical trial

Bomhof, Marc R, Parnell, Jill A, Ramay, Hena R, Crotty, Pam, Rioux, Kevin P, Probert, Chris S ORCID: 0000-0003-0477-6714, Jayakumar, Saumya, Raman, Maitreyi and Reimer, Raylene A (2019) Histological improvement of non-alcoholic steatohepatitis with a prebiotic: a pilot clinical trial EUROPEAN JOURNAL OF NUTRITION, 58 (4). pp. 1735-1745. ISSN 1436-6207, 1436-6215

Text NASH Prebiotic Manuscript_Submitted May 8.docx - Author Accepted Manuscript Download (1MB)

Abstract

Purpose: In obesity and diabetes the liver is highly susceptible to abnormal uptake and storage of fat. In certain individuals hepatic steatosis predisposes to the development of non-alcoholic steatohepatitis (NASH), a disease marked by hepatic inflammation and fibrosis. Although the precise pathophysiology of NASH is unknown, it is believed that the gut microbiota-liver axis influences the development of this disease. With few treatment strategies available for NASH, exploration of gut microbiota-targeted interventions is warranted. We investigated the therapeutic potential of a prebiotic supplement to improve histological parameters of NASH. Methods: In a placebo-controlled, randomized pilot trial, 14 individuals with liver-biopsy-confirmed NASH [non-alcoholic fatty liver activity score (NAS) ≥ 5] were randomized to receive oligofructose (8 g/day for 12 weeks followed by 16 g/day for 24 weeks) or isocaloric placebo for 9 months. The primary outcome measure was the change in liver biopsy NAS score and the secondary outcomes included changes in body weight, body composition, glucose tolerance, inflammatory markers, and gut microbiota. Results: Independent of weight loss, oligofructose improved liver steatosis relative to placebo and improved overall NAS score (P = 0.016). Bifidobacterium was enhanced by oligofructose, whereas bacteria within Clostridium cluster XI and I were reduced with oligofructose (P < 0.05). There were no adverse side effects that deterred individuals from consuming oligofructose for treatment of this disease. Conclusions: Independent of other lifestyle changes, prebiotic supplementation reduced histologically-confirmed steatosis in patients with NASH. Larger follow-up studies are warranted. Clinical Trial: This trial was registered at Clinicaltrials.com as NCT03184376.

Item Type:	Article
Uncontrolled Keywords:	Non-alcoholic steatohepatitis, Gut microbiota, Prebiotic, Oligofructose
Depositing User:	Symplectic Admin
Date Deposited:	07 Aug 2018 06:25
Last Modified:	16 Jun 2026 07:02
DOI:	10.1007/s00394-018-1721-2
Related Websites:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3024663
Disclaimer:	The University of Liverpool is not responsible for content contained on other websites from links within repository metadata. Please contact us if you notice anything that appears incorrect or inappropriate.